Vaginal primary malignant melanoma: report of four cases and review of the literature

Objective: The aim of this retrospective study was to analyse the clinical characteristics, management and prognosis of four patients with vaginal primary malignant melanoma (VPMM) who were diagnosed and treated in our departments together with a review of the current literature. Materials and methods: Between January 1997 and September 2009, four cases with histologically confirmed VPMM were evaluated retrospectively. All patients underwent wide local excision. Results: One patient was in Stage I (25%), two patients in Stage II (50%) and one patient in Stage IV (25%). Among them, one patient received additional radiotherapy and three patients received additional immunotherapy with interferon. Conclusion: The prognosis of VPMM is very poor, despite the treatment modality, because most cases are diagnosed at late stage.

Vaginal primary malignant melanoma; Treatment; Radiotherapy; Chemotherapy; Immunotherapy; Prognosis

[1] Creasman W.T., Phillips J.L., Menck H.R.: “The National Cancer Data Base report on cancer of the vagina”. Cancer, 1998, 83,1033.

[2] Piura B.: “Management of primary melanoma of the female urogenital tract”. Lancet Oncol., 2008, 9, 973.

[3] Weinstock M.A.: “Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival”. Am. J. Obstet. Gynecol., 1994, 171, 1225.

[4] Gökaslan H., Sis¸manog˘lu A., Pekin T., Kaya H., Ceyhan N.: “Primary malignant melanoma of the vagina: a case report and review of the current treatment options”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2005, 121, 243.

[5] Irvin W.P. Jr., Bliss S.A., Rice L.W., Taylor P.T. Jr., Andersen W. A.: “Malignant melanoma of the vagina and locoregional control: radical surgery revisited”. Gynecol. Oncol., 1998, 71, 476.

[6] Piura B., Rabinovich A., Yanai-Inbar I.: “Primary malignant melanoma of the vagina: case report and review of literature”. Eur.

J. Gynaecol. Oncol., 2002, 23, 195.

[7] Reid G.C., Schmidt R.W., Roberts J.A., Hopkins M.P., Barrett

R. J., Morley G.W.: “Primary melanoma of the vagina: a clinicopathologic analysis”. Obstet. Gynecol., 1989, 74, 190.

[8] Hauspy J., Nevin A., Harley I., Mason W., Quirt I., Ghazarian D., Laframboise S.: “Paraneoplastic syndrome in vaginal melanoma: a case report and review of the literature”. Int. J. Gynecol. Cancer, 2007, 17, 1159.

[9] Levitan Z., Gordon A.N., Kaplan A.L., Kaufman R.H.: “Primary malignant melanoma of the vagina: report of four cases and review of the literature”. Gynecol. Oncol., 1989, 33, 85.

[10] Nigogosyan G., Delapava S., Pickren J.W.: “Melanoblasts in vaginal mucosa: origin for primary malignant melanoma”. Cancer, 1964, 17, 912.

[11] Allen A.C., Spitz S.: “Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis”. Cancer, 1953, 6, 1.

[12] Moros M.L., Ferrer F.P., Mitchell M.J., Romeo J.A., Lacruz R.L.: “Primary malignant melanoma of the vagina. Poor response to radical surgery and adjuvant therapy”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 113, 248.

[13] Chung A.F., Casey M.J., Flannery J.T., Woodruff J.M., Lewis J.L. Jr.: “Malignant melanoma of the vagina-report of 19 cases”. Obstet. Gynecol., 1980, 55, 720.

[14] Miner T.J., Delgado R., Zeisler J., Busam K., Alektiar K., Barakat R., Poynor E.: “Primary vaginal melanoma: a critical analysis of therapy”. Ann. Surg. Oncol., 2004, 11, 34.

[15] Batsakis J.G., Suarez P.: “Mucosal melanomas: a review”. Adv. Anat. Pathol., 2000, 7, 167.

[16] Borazjani G., Prem K.A., Okagaki T., Twiggs L.B., Adcock L.L.: “Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases”. Gynecol. Oncol., 1990, 37, 264.

[17] Gupta D., Malpica A., Deavers M.T., Silva E.G.: “Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases”. Am. J. Surg. Pathol., 2002, 26, 1450.

[18] Pandey M., Mathew A., Abraham E.K., Ahamed I.M., Nair K.M.: “Primary malignant melanoma of the mucous membranes”. Eur. J. Surg. Oncol., 1998, 24, 303.

[19] Nakagawa S., Koga K., Kugu K., Tsutsumi O., Taketani Y.: “The evaluation of the sentinel node successfully conducted in a case of malignant melanoma of the vagina”. Gynecol. Oncol., 2002, 86, 387.

[20] Chang A.E., Karnell L.H., Menck H.R.: “The National Cancer Data Base report on cutaneous and noncutaneous melanoma: asummary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society”. Cancer, 1998, 83, 1664.

[21] Reeves M.E., Coit D.G.: “Melanoma. A multidisciplinary approach for the general surgeon”. Surg. Clin. North Am., 2000, 80, 581.

[22] Abramova L., Parekh J., Irvin W.P. Jr., Rice L.W., Taylor P.T. Jr., Anderson W.A., Slingluff C.L. Jr.: “Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review”. Ann. Surg. Oncol., 2002, 9, 840.

[23] Petru E., Nagele F., Czerwenka K., Graf A.H., Lax S., Bauer M. et al.: “Primary malignant melanoma of the vagina: long-term remission following radiation therapy”. Gynecol. Oncol., 1998, 70, 23.

[24] Buchanan D.J., Schlaerth J., Kurosaki T.: “Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature”. Am. J. Obstet. Gynecol., 1998, 178, 1177.

[25] Signorelli M., Lissoni A.A., Garbi A., Perego P., Mangioni C.: “Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review”. Gynecol. Oncol., 2005, 97, 700.

[26] Middleton M.R., Grob J.J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S. et al.: “Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma”. J. Clin. Oncol., 2000, 18, 158.

[27] Androutsopoulos G., Adonakis G., Ravazoula P., Kourounis G.: “Primary malignant melanoma of the vagina: a case report”. Eur. J. Gynaecol. Oncol., 2005, 26, 661.

[28] Jack A., Boyes C., Aydin N., Alam K., Wallack M.: “The treatment of melanoma with an emphasis on immunotherapeutic strategies”. Surg. Oncol., 2006, 15, 13.

[29] Ives N.J., Stowe R.L., Lorigan P., Wheatley K.: “Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients”. J. Clin. Oncol., 2007, 25, 5426.

[30] Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., Shoenfeld Y.: “Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies”. Ann. Rheum. Dis., 2001, 60, 433.

[31] Keilholz U., Conradt C., Legha S.S., Khayat D., Scheibenbogen C., Thatcher N. et al.: “Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients”. J. Clin. Oncol., 1998, 16, 2921.

[32] Harting M.S., Kim K.B.: “Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma”. Melanoma Res., 2004, 14, 517.